IMCR
Immunocore Holdings Plc
NASDAQ · Healthcare · Biotechnology · GB
$29.23
−2.66%Year over year
Reported trailing growth
- Revenue
- +13.4%
- EBITDA
- +2146.0%
- EBIT
- +62.4%
- EPS
- +56.0%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +21.0%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +27.3%
- EBITDA
- +101.0%
- EBIT
- +40.1%
- Net income
- +35.3%
- EPS
- +48.0%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026